Outcomes of children with rhabdomyosarcoma treated with intensive chemotherapy, surgery, and radiotherapy through a period of protocol revision at a South African center, 1990-2010. 
A total of 75 children with biopsy-proven rhabdomyosarcoma were treated at our institution between 1990 and 2010.  Five-year overall survival (OS) for the entire cohort was 58.7%.  OS by stage was as follows: Stage 1 (80%), Stage 2 (80%), Stage 3 (54.1%), and Stage 4 (38.5%).  There was a trend to suggest that revision of treatment approaches improved crude survival over time: pre-2003 (OS 42.1%); 2003-2005 (OS 50.0%); 2005-2010 (OS 60.8%).